ангиотензин转换基因和缺氧运动耐受性:一个随机交叉试验
Yuki Muramoto1,1, Mizuki Momoi2,1, Daisuke Nakashima3
1Institute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo, Japan.
International journal of sports medicine
|January 9, 2025
概括
遗传因素会影响运动员容忍低氧训练的程度. 血管素转化酶 (ACE) -II基因型与在低氧环境中炼期间最大氧气摄取量减少和乳酸盐水平降低有关.
科学领域:
- 运动生理学 运动生理学
- 人类遗传学 人类遗传学
- 运动科学 运动科学 运动科学
背景情况:
- 已知低氧训练可以提高耐力表现.
- 由于生理差异,对低氧条件的个体反应有很大差异.
- 了解这些变异的遗传基础对于优化训练至关重要.
研究的目的:
- 在低氧条件下调查遗传多态性和运动耐受性之间的关系.
- 确定影响低氧生理反应的特定遗传因素.
- 为了确定基因分析是否可以为个性化缺氧训练策略提供信息.
主要方法:
- 一项随机交叉研究,涉及22名男性大学生.
- 增量负载测试在正常和低氧条件下使用人体测量仪进行.
- 分析了氧气吸收的峰值,血液中的乳酸盐水平,以及16种与运动耐受性相关的基因型,包括血管激素转化酶 (ACE) 基因.
主要成果:
- 在低氧条件下,峰值氧气吸收显著减少 (p<0.01).
- 峰值氧气吸收减少 (Δ峰值氧气吸收) 的个体差异很大.
- 与ACE-ID/ACE-DD基因型相比,ACE-II基因型的参与者在正常和缺氧条件下显著减少了峰值氧气吸收和降低了血中乳酸盐水平 (p=0.02为Δ峰值氧气吸收).
结论:
- 血管酶转化酶 (ACE) 基因型影响运动耐受性和对缺氧的生理反应.
- 具有ACE-II基因型的个体可能会在低氧环境中经历更大的性能下降和乳酸代谢变化.
- 个人化缺氧训练计划包括遗传分析,特别是专注于ACE基因型,建议优化耐力运动的耐受性.
更多相关视频
10:18Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
Published on: June 29, 2014
17.1K
06:28A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
Published on: April 28, 2023
779
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
472
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
472
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381